Source comparison
Quickcomparison
Dose Range KPV (Alpha-MSH Fragment) 200 mcg–1500 mcg mcg BPC-157 250–500 mcg Frequency Once daily Administration Oral Subcutaneous injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3
This comparison does not assign a generated winner or score.
- Dose Range
- KPV (Alpha-MSH Fragment)
- 200 mcg–1500 mcg mcg
- BPC-157
- 250–500 mcg
- Frequency
- Once daily
- Administration
- Oral
- Subcutaneous injection
- Cycle Length
- Ongoing/indefinite
- 4-6 weeks
- Onset Speed
- Moderate (1-2 weeks)
- Evidence Level
- Strong human trials (Phase 3 or FDA approved)
- Strong preclinical (extensive animal studies)
- Efficacy